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Background:  Iron deficiency (ID) is an ominous co-morbidity commonly found in patients with systolic heart failure (HF), and iron therapy 
is presumed to bring clinical benefits.
methods:  We performed a meta-analysis of all randomized control trials that compared the effects of intravenous iron therapy with either 
no therapy or placebo in iron deficient patients with systolic HF (both anaemics and non-anaemics). We searched electronic databases 
(PubMed) up to September 2014.
results:  We identified 6 trials which fulfilled the inclusion criteria, and in total 542 patients received intravenous iron therapy (454 - ferric 
carboxymaltose, 88 - iron sucrose) in comparison to 381 control patients. Intravenous iron therapy in iron deficient patients with systolic 
HF has been shown to reduce the risk of combined cardiovascular hospitalization or death (OR=0.41, 95%CI: 0.29-0.58, p<0.001, I2=0%) 
and the risk of HF hospitalization (OR=0.31, 95%CI: 0.17-0.55, p<0.001, I2=0%). The analysis revealed no effect on either all-cause or 
cardiovascular mortality (both p>0.2), which may be due to a low number of reported deaths (n=28 (5%) vs n=32 (8%) for those treated vs 
not treated with intravenous iron). Moreover, intravenous iron therapy resulted in a reduction in NYHA class (data are reported as a mean 
net effect with 95% confidence intervals for all continuous variables) (-0.39 class, 95%CI: -0.48 - -0.29, p<0.001, I2=92%), an increase in 
6-minute walking test distance (+31m, 95%CI: 19-43, p<0.001, I2=0%), and an improvement in quality of life in patients with systolic heart 
failure (KCCQ score: +5.4 points, 95%CI: 2.8-7.9, p<0.001, I2=0%, EQ-5D score: +3.9 points, 95%CI: 1.5-6.2, p<0.01, I2=45%, MLHFQ 
score: -19 points, 95%CI: -23 - -16, p<0.001, I2=0%).
conclusion:  Intravenous iron therapy in iron deficient patients with systolic HF reduces hospitalization rates, alleviates HF symptoms, and 
improves exercise capacity and quality of life.
